- Conditions
- Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
- Interventions
- Pitolisant
- Drug
- Lead sponsor
- Harmony Biosciences Management, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–40
of 16
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Narcolepsy Type 2
- Interventions
- TAK-360, Placebo
- Drug · Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 31
- States / cities
- Auburn, Alabama • Chandler, Arizona • Chula Vista, California + 26 more
- Conditions
- Excessive Daytime Sleepiness, Cataplexy, Narcolepsy
- Interventions
- FT218, Placebo
- Drug
- Lead sponsor
- Avadel
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 38
- States / cities
- Anniston, Alabama • Auburn, Alabama • Birmingham, Alabama + 32 more
- Conditions
- Hypersomnia, Primary Hypersomnia, Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
- Interventions
- Flumazenil
- Drug
- Lead sponsor
- Lynn Marie Trotti
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Hypersomnia, Idiopathic Hypersomnia, Narcolepsy
- Interventions
- Clarithromycin followed by placebo, Placebo then Clarithromycin
- Drug
- Lead sponsor
- Lynn Marie Trotti
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Narcolepsy, Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
- Interventions
- Brief MBI, Standard MBI, Extended MBI
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hypersomnia
- Interventions
- Transcranial Direct Current Stimulation, Sham stimulation
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Intracerebral Hemorrhage
- Interventions
- NXY-059
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 61 more
- Conditions
- Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke, Ischemic Attack, Transient
- Interventions
- NXY-059
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 95 more
- Conditions
- Narcolepsy Type 1, Narcolepsy Type 2
- Interventions
- cleminorexton, Placebo
- Drug
- Lead sponsor
- Centessa Pharmaceuticals (UK) Limited
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Colorado Springs, Colorado • Brandon, Florida + 14 more
- Conditions
- Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
- Interventions
- TAK-994, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 36
- States / cities
- Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 31 more
- Conditions
- Narcolepsy
- Interventions
- SEP363856, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- Orange, California • St. Petersburg, Florida • Atlanta, Georgia + 3 more
- Conditions
- Narcolepsy
- Interventions
- sodium oxybate
- Drug
- Lead sponsor
- Orphan Medical
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • La Jolla, California • Stanford, California + 31 more
- Conditions
- Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
- Interventions
- CEP-10953 (Armodafinil)
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 41
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 35 more
- Conditions
- Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
- Interventions
- AXS-12 (reboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 47
- States / cities
- Alabaster, Alabama • Peoria, Arizona • Phoenix, Arizona + 43 more
- Conditions
- Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
- Interventions
- AXS-12 (Reboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Alameda, California • Santa Ana, California + 11 more